Intellia Therapeutics Inc NTLA:NASDAQ

Last Price$130.47Cboe Real-Time Last Sale as of 10:35AM ET 10/18/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.02(0.02%)
Bid (Size)$129.55 (100)
Ask (Size)$130.55 (100)
Day Low / High$128.31 - 131.54
Volume89.9 K
 

View Biotechnology IndustryPeer Comparison as of 10/18/2021

 

Intellia Therapeutics Inc ( NASDAQ )

Price: $130.47
Change: -0.02 (0.02%)
Volume: 89.9 K
10:35AM ET 10/18/2021
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $104.27
Change: -0.27 (0.26%)
Volume: 25.1 K
10:34AM ET 10/18/2021
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $174.39
Change: -3.89 (2.18%)
Volume: 52.8 K
10:34AM ET 10/18/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Acceleron Pharma Inc ( NASDAQ )

Price: $173.97
Change: +1.03 (0.60%)
Volume: 122.1 K
10:29AM ET 10/18/2021
 

Read more news Recent News

Insider Sell: Intellia Therapeutics
4:34PM ET 10/13/2021 MT Newswires

John F Crowley, Director, on October 11, 2021, sold 2,500 shares in Intellia Therapeutics (NTLA) for $298,875. Following the Form 4 filing with the SEC,...

Intellia Therapeutics, SparingVision Sign Deal to Develop Ocular Therapies
7:47AM ET 10/13/2021 MT Newswires

Intellia Therapeutics (NTLA) and SparingVision said they have signed a deal to develop medicines to treat ocular diseases. SparingVision will be given...

Insider Sell: Intellia Therapeutics
9:27AM ET 10/08/2021 MT Newswires

John F Crowley, Director, on October 05, 2021, sold 10,000 shares in Intellia Therapeutics (NTLA) for $1,305,391. Following the Form 4 filing with the SEC,...

Intellia Therapeutics Gets New Zealand Ok to Start Phase 1/2 Clinical Trial of Hereditary Angioedema Treatment
8:08AM ET 10/06/2021 MT Newswires

Intellia Therapeutics (NTLA) said Wednesday it has received approval from the New Zealand Medicines and Medical Devices Safety Authority to start a phase...

Company Profile

Business DescriptionIntellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address40 Erie Street
Cambridge, Massachusetts 02139
Phone+1.857.285.6200
Number of Employees211
Recent SEC Filing09/09/20214
President, Chief Executive Officer & DirectorJohn M. Leonard
Executive VP, Chief Financial & Accounting OfficerGlenn Goddard
Chief Scientific Officer & Executive VPLaura Sepp-Lorenzino
Chief Medical Officer & Executive Vice PresidentDavid Lebwohl

Company Highlights

Price Open$129.77
Previous Close$130.49
52 Week Range$22.17 - 202.73
Market Capitalization$9.6 B
Shares Outstanding73.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/04/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.86
Beta vs. S&P 500N/A
Revenue$30.4 M
Net Profit Margin-442.58%
Return on Equity-39.01%

Analyst Ratings as of 10/04/2021

Buy
13
Overweight
2
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset